This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.
Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans
by Zacks Equity Research
Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
Pharma ETFs in Focus Post Q4 Earnings
by Sweta Killa
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
Top Stock Reports for Alphabet, Pfizer & Uber
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Pfizer (PFE), and Uber Technologies (UBER).
J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.
Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates
by Kinjel Shah
Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.
Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.
Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track
by Zacks Equity Research
Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.
Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data
by Zacks Equity Research
Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.
Markets Return to Normalcy
by Zacks Equity Research
Markets Return to Normalcy
Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS
by Mark Vickery
We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.
Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat
by Zacks Equity Research
Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.
Pfizer (PFE) Misses Q4 Earnings Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of -8.70% and 6.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Markets Await Economic and Earnings Data
by Zacks Equity Research
Markets Await Economic and Earnings Data
J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III
by Zacks Equity Research
J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.
Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT
by Zacks Equity Research
Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.
Did r/WallStreetBets Smother the Bull Market?
by John Blank
Institutional traders are taking profits off the table, respecting very rich, fully priced in, stock market valuations. However, there is a lot of risk de-leveraging and capital building going on, too.
Another Big Week for Q4 Earnings, Econ News; ON Semi Beats
by Mark Vickery
Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.
Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview
by Zacks Equity Research
Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview
Buy Pharma Giant AbbVie Stock Before Q4 Earnings for Dividend and Value?
by Benjamin Rains
Let's check out AbbVie to see if investors might want to buy the stock ahead of its fourth quarter fiscal 2020 financial release that's due out before the opening bell on Wednesday, Feb. 3...
Earnings Strength and Market Weakness
by Sheraz Mian
Market volatility notwithstanding, we have to acknowledge that the fundamental backdrop, as reflected in the outlook for earnings and interest rates, remains very favorable...
Pfizer's (PFE) Key Brands Likely to Drive Its Q4 Earnings
by Zacks Equity Research
Pfizer's (PFE) Biopharma unit becomes the "New Pfizer" following the separation of the Upjohn unit. The Q4 announcement will the first quarterly result for the "New Pfizer".
Personal Income Increased in December
by Zacks Equity Research
Personal Income Increased in December
Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.